Treatment progress of phlebotomy for polycythemia vera
10.13303/j.cjbt.issn.1004-549x.2025.08.018
- VernacularTitle:真性红细胞增多症放血治疗的研究进展
- Author:
Yanjie YANG
1
;
Ranran QIN
1
;
Ruiqin HOU
1
Author Information
1. Department of Blood Transfusion, Peking University People's Hospital, Beijing 100044, China
- Publication Type:Journal Article
- Keywords:
polycythemia vera;
phlebotomy;
neoplasm
- From:
Chinese Journal of Blood Transfusion
2025;38(8):1113-1119
- CountryChina
- Language:Chinese
-
Abstract:
Polycythemia vera (PV) is a BCR-ABL1-negative myeloproliferative neoplasm characterized by the proliferation of all three hematopoietic cell lines to varying degrees. It is commonly associated with mutations such as JAK2 V617F or mutations in exon 12 of the JAK2 gene. These genetic alterations contribute to a range of clinical manifestations, including thrombosis, bleeding tendencies, splenomegaly, and disturbances in microcirculation. Phlebotomy serves as a first-line therapeutic approach for PV by reducing hematocrit levels to a target below 45%, which effectively decreases blood viscosity and thereby lowers the risk of thrombosis. As such, phlebotomy plays a crucial role in the management of PV. This review systematically summarizes recent research advances on phlebotomy for PV, aiming to support the development of individualized treatment approaches for patients with PV.
